Predictive diagnostics developer KIYATEC has partnered with Greenville Health System (GHS) Cancer Institute to study its new range of diagnostic tests to predict the response of ovarian cancer patients to chemotherapy before providing treatment.

Within next year, the organisations plan to extend the clinical studies of the tests to patients suffering from other types of cancer.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Results from the study will be used to inform treatment decisions and gain a better understanding of the potential success of these treatments.

The predictive tests are also expected to minimise the stress and pain caused due to less information on the patient-specific response.

During the studies, a patient’s cancer cells will be transferred to a three-dimensional (3D) cell culture at the KIYATEC laboratories.

“Results from the study will be used to inform treatment decisions and gain a better understanding of the potential success of these treatments.”

The 3D cultures, which are designed to accurately reproduce the biologic and physiologic interactions of natural human cells, will be treated with different chemotherapies and cancer-treatment drugs.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Various concentrations of the therapies will be assessed to establish a cell’s drug response level, which will then be used to predict patient responsiveness to a specific treatment.

KIYATEC CEO Matthew Gevaert said: “Human cells are as unique as the patients themselves, so you really need to see the way those cells interact with given drugs to know for certain what treatment will work.

“By placing each patient’s cancer cells in conditions that mimic the actual human body, we can drill down to drug effect on the cellular level and establish the connection between the results we see in the lab and the response we hope to see in the patients.”